Fang X.-H.,Luoyang Dongfang Hospital |
Wu Q.,Luoyang Dongfang Hospital |
Han X.-M.,Luoyang Dongfang Hospital |
Ren X.-L.,Luoyang Dongfang Hospital |
And 5 more authors.
Tumor | Year: 2013
bjective: To investigate the efficacy of pemetrexed as a second-line treatment for patients with NSCLC (advanced non-small cell lung cancer). Methods: Fifty-six patients with stages III B-IV NSCLC, who failed in the first-line cisplatin-based chemotherapy, were enrolled in this study between January 2008 and January 2012. All the patiients received pemetrexed 500 mg/m2 on day 1 and repeated every 21 days as a second-line chemotherapy. After two cycles of chemotherapy, the clinical efficacy and the adverse effects were evaluated. The median survival time and the one-year survival rate were calculated. Results: All the patients received 2-6 cycles of the chemotherapy with a total of 178 cycles. All patients were evaluable. Of the 56 patients, no one achieved complete response, 9 (16.1%) achieved partial response, 10 (33.9%) achieved stable disease, 28 (50.0%) achieved progressive disease. The objective response rate was 16.1% (9/56). The median survival time was 8.9 months, and the one-year survival rate was 30.35%. The common adverse effects were bone marrow suppression and gastrointestinal toxicities with a light severity and could be tolerable. No treatment-related deaths occurred. Conclusion: Chemotherapy with pemetrexed as a second-line treatment for advanced NSCLC has a definite efficacy, and the adverse effects can be tolerable. Copyright © 2013 by TUMOR.